Evidence map›Paper›PMID 33880447›Full record

ArticleNeuro-oncology advances

Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival.

Calixto-Hope G Lucas, Harish N Vasudevan, William C Chen, Stephen T Magill, Steve E Braunstein, Line Jacques, Sonika Dahiya, Fausto J Rodriguez, Andrew E Horvai, Arie Perry and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Loss of H3K27me3 expression in canine nerve sheath tumors.Frontiers in veterinary science · 2022
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Calixto-Hope G LucasDepartment of Pathology, University of California, San Francisco, California, USA.ORCID 0000-0002-8347-9592
Harish N VasudevanDepartment of Radiation Oncology, University of California, San Francisco, California, USA.
William C ChenDepartment of Radiation Oncology, University of California, San Francisco, California, USA.
Stephen T MagillDepartment of Neurological Surgery, University of California, San Francisco, California, USA.ORCID 0000-0002-5257-7835
Steve E BraunsteinDepartment of Radiation Oncology, University of California, San Francisco, California, USA.
Line JacquesDepartment of Neurological Surgery, University of California, San Francisco, California, USA.ORCID 0000-0002-2691-587X
Sonika DahiyaDepartment of Pathology and Immunology, Washington University, St. Louis, Missouri, USA.ORCID 0000-0002-5585-0964
Fausto J RodriguezDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-8662-1219
Andrew E HorvaiDepartment of Pathology, University of California, San Francisco, California, USA.
Arie PerryDepartment of Pathology, University of California, San Francisco, California, USA.
Melike PekmezciDepartment of Pathology, University of California, San Francisco, California, USA.
David R RaleighDepartment of Radiation Oncology, University of California, San Francisco, California, USA.

Funding

Understanding How Ciliary Hedgehog Signaling Causes MedulloblastomaK08CA212279 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RALEIGH, DAVID R · 2017 to 2021
$886k
NCI NIH HHS K08 CA212279
6 · The paper itself

Abstract

backgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive and poorly understood malignant neoplasm. Even in the setting of multimodal therapy, the clinical course of MPNST is frequently marked by metastatic conversion and poor overall prognosis, with optimal treatment paradigms for this rare tumor unknown.

methodsWe reviewed the medical records and histopathology of 54 consecutive patients who were treated at University of California San Francisco between 1990 and 2018.

resultsOur cohort consisted of 24 male and 30 female patients (median age 38 years). Fédération Nationale des Centres de Lutte Contre Le Cancer (FNCLCC) sarcoma grading criteria segregated patients into groups with differences in overall survival (OS) (

conclusionsOur results lend support to the FNCLCC sarcoma grading criteria as a prognostic scheme for MPNST, although few cases of grade 1 were included. Further, we identify increased Ki-67 labeling as a strong predictor of poor OS from MPNST. Finally, we identify a subset of MPNSTs with a predictive immunohistochemical profile that has improved local control with adjuvant radiotherapy. These data provide insights into the grading and therapy for patients with MPNST, although further studies are needed for independent validation.

Indexed as

clinical outcomesFédération Nationale des Centres de Lutte Contre Le Cancerimmunohistochemistrymalignant peripheral nerve sheath tumorradiotherapy

Identifiers

PMID33880447
PMCPMC8044670

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.